A phase II clinical trial has been conducted to evaluate the safety of a treatment, BI 1358894, in patients with major depressive disorder. The trial's results may also provide insight into the treatment's efficacy and tolerability, although some reports suggest the trial may have focused on patients with inadequate response to antidepressants or borderline personality disorder. The treatment, a TRPC4/5 inhibitor, is being investigated for potential use in various mental health conditions.